Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425228 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL10511364 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL30655986 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL29009630 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL31006936 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL2510639 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL6384699 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL1673169 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL702670 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL2693783 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3655029-B1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-03-18 | — | — | EP | claimed |
| EP-4687966-A2 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250121067-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | TRAIT BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | claimed |
| EP-4531836-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | Trait Biosciences, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| US-20240325515-A1 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER (US) | 2024-10-03 | — | — | US | claimed |
| WO-2024201324-A2 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF | PFIZER INC. (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| US-20230405137-A1 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER (US) | 2023-12-21 | — | — | US | claimed |
| WO-2023235386-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | TRAIT BIOSCIENCES, INC. (US) | 2023-12-07 | — | — | WO | claimed |
| EP-4243863-A2 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF | Pfizer Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| EP-3655029-A1 | IMMUNOGENIC COMPOSITION | GlaxoSmithKline Biologicals SA (BE) | 2020-05-27 | — | — | EP | claimed |
| EP-3177325-B1 | MODIFIED HOST CELLS AND HYBRID OLIGOSACCHARIDES FOR USE IN BIOCONJUGATE PRODUCTION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-04-01 | — | — | EP | claimed |
| US-20190282682-A1 | MODIFIED HOST CELLS AND HYBRID OLIGOSACCHARIDES FOR USE IN BIOCONJUGATE PRODUCTION | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2019-09-19 | — | — | US | claimed |
| US-20190248841-A1 | Immunogenic Composition | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-08-15 | — | — | US | claimed |
| US-10307474-B2 | Modified host cells and hybrid oligosaccharides for use in bioconjugate production | GLAXOSMITHKLINE BIOLOGICALS S.A. | 2019-06-04 | — | — | US | claimed |
| WO-2019016188-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-01-24 | — | — | WO | claimed |
| WO-2019016187-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-01-24 | — | — | WO | claimed |
| US-20170232093-A1 | MODIFIED HOST CELLS AND HYBRID OLIGOSACCHARIDES FOR USE IN BIOCONJUGATE PRODUCTION | GLYCOVAXYN AG (CH) | 2017-08-17 | — | — | US | claimed |
| EP-3177325-A2 | MODIFIED HOST CELLS AND HYBRID OLIGOSACCHARIDES FOR USE IN BIOCONJUGATE PRODUCTION | Glycovaxyn AG (CH) | 2017-06-14 | — | — | EP | claimed |
| WO-2016020499-A2 | MODIFIED HOST CELLS FOR USE IN BIOCONJUGATE PRODUCTION | GLYCOVAXYN AG (CH) | 2016-02-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325515-A1 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | GALNT13, FUT5, CD47 | PAX8 1065/4885ALDH1A1 4370/4885 |
| US-20250121067-A1 | WATER-SOLUBLE CANNABINOID PRODRUGS COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | CNR2, CNR1, BSG | PAX8 2240/4885ALDH1A1 3697/4885 |
| US-20230405137-A1 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | GALNT13, FUT5, CD47 | PAX8 1065/4885ALDH1A1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.